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Epstein–Barr virus (EBV) BMRF-2 protein interaction with the β1 family of integrins plays an important role in EBV infection of polarized
oral epithelial cells. In this work, we characterized BMRF-2 protein expression in EBV-infected B lymphoblastoid and polarized oral epithelial
cells, and in hairy leukoplakia (HL) epithelium. BMRF-2 expression in B cells and polarized oral epithelial cells was associated with the EBV lytic
infection. In these cells, BMRF-2 is efficiently transported to the cell membrane and its integrin binding Arg–Gly–Asp (RGD) motif is exposed on
the cell surface. BMRF-2 is highly expressed in HL epithelium and accumulates at the lateral border of oral keratinocytes. In EBV-infected
polarized oral epithelial cells, this protein is transported to the basolateral membranes and co-localized with β1 integrin. These data suggest that
BMRF-2 may play an important role in cell-to-cell spread of EBV within the oral epithelium. BMRF-2 is glycosylated through O-linked
oligosaccharides; it forms oligomers and is associated with the virion envelope. Its C-terminal tail is localized in the cytoplasm. We found that β1,
α5, and α3 integrins are present in purified EBV virions. We show that BMRF-2 is a ligand for β1, α5, α3, and αv integrins and our data are
consistent with a role for BMRF-2 in viral lytic infection.
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Epstein–Barr virus (EBV), a member of the gammaherpes-
virus family, is associated with neoplasia of lymphoid and
epithelial cell origin. EBV-related diseases include Burkitt's
lymphoma, Hodgkin's disease, infectious mononucleosis,
nasopharyngeal carcinoma, certain adult T-cell lymphomas,
gastric carcinoma, and oral hairy leukoplakia (HL) (Rickinson
and E, 2001). EBV tropism is restricted mainly to B lym-
phocytes and squamous epithelium, causing latent and produc-
tive infection, respectively (Rickinson and E, 2001). EBVentry
into B lymphocytes or epithelial cells is mediated by the
interactions of viral glycoproteins and their cell surface
receptors or co-receptors: gp350/220 binds to its cellular
CR2-type 2 complement receptor, CD21 (Fingeroth et al.,
1984; Tanner et al., 1987), resulting in viral entry into B cells.⁎ Corresponding author. Department of Medicine and Department of Orofacial
Sciences, University of California, San Francisco, 513 Parnassus, San Francisco,
CA 94143, USA. Fax: +1 415 476 9364.
E-mail address: tugizov@itsa.ucsf.edu (S.M. Tugizov).
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doi:10.1016/j.virol.2006.09.047Complexes of viral glycoproteins–gH/gL/gp42 and gH/gL–are
required for infection of B lymphocytes and epithelial cells,
respectively (Molesworth et al., 2000; Wang et al., 1998). The
binding of EBV gp42 to its co-receptor HLA class II molecule
functions as a switching factor for viral tropism between B
lymphocytes and epithelial cells (Borza and Hutt-Fletcher,
2002; Li et al., 1997). We have shown that the interactions of
BMRF-2 with β1 family integrins play a critical role in the
infection of polarized oropharyngeal epithelial cells with EBV
(Tugizov et al., 2003).
The mucosal epithelium of the oropharyngeal surface may
serve as a portal of entry for EBV during primary infection and
as the pathway of exit for progeny virions during systemic
infection. Productive EBV infection of the oral mucosal
epithelium has been shown in HL (Greenspan et al., 1985),
which is associated primarily with HIV/AIDS-mediated
immunodeficiency (Greenspan and Greenspan, 1997; Green-
span et al., 1985, 1987; Walling, 2000). EBV infection in HL is
restricted to the terminally differentiated part of the mucosal
epithelium (Niedobitek et al., 1991; Sandvej et al., 1992; Young
et al., 1991) and is absent in the lower basal and parabasal
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understood. Analysis of an HL cDNA library showed abundant
mRNA expression of the BMRF-2 gene in the oral epithelium
of HL, confirmed by in situ hybridization studies showing high-
level expression of BMRF-2 in the more differentiated stratum
spinosum cell layers (Palefsky et al., 1997; Penaranda et al.,
1997).
The BMRF-2 protein was first identified as a glycoprotein by
Modrow et al. (1992) in EBV-positive B-cell lines treated with
TPA/butyric acid to induce lytic EBV infection. The BMRF-2
open-reading frame (ORF) is conserved throughout the
gammaherpesvirus family (Coulter and Reid, 2002), suggesting
that it may be important in the viral life cycle. It is located
between the BMRF1 and BMLF1 genes in the M region of the
EBV genome, defined by restriction digestion with BamHI.
Using BMRF-2-specific probes, Becker et al. detected two
mRNA species (3.7 and 2.1 kb) in EBV-transformed normal
lymphoblasts and in one ataxia-telangiectasia cell line (Becker
et al., 1988). The larger mRNA species are bicistronic, encoding
both BMRF-1 and BMRF-2 proteins. The smaller species are
believed to be transcribed from BMRF-2's own promoter,
which is located within the ORF of BMRF-1. We have
previously shown that the activity of the BMRF-2 promoter is
up-regulated by mechanisms known to induce differentiation of
epithelial cells (Lagenaur and Palefsky, 1999).
The BMRF-2 protein contains an Arg–Gly–Asp (RGD)
motif that binds to β1 and α5 integrins; this interaction mediates
the entry of EBV through the basolateral membranes of
polarized oral epithelial cells (Tugizov et al., 2003). Integrins
are a large family of heterodimeric cell surface receptors
consisting of 18α and 8β subunits (Brakebusch and Fassler,
2005; Giancotti and Ruoslahti, 1999). There are more than 27
heterodimers and each mammalian cell expresses several
combinations of αβ subunits. Most cell surface integrins bind
to extracellular matrix proteins (ECM) via their RGD motif, and
mediate cell–ECM and cell–cell adhesion, interactions that are
critical for many functions of mammalian cells including
growth, differentiation, apoptosis, endocytosis, attachment and
motility (Giancotti and Ruoslahti, 1999; Takagi, 2004). Several
viral proteins from either enveloped or non-enveloped viruses
also possess the RGD motif, which may be involved in binding
virions to cell surface integrins. Enveloped viruses such as
human herpesvirus 8 (HHV-8) (Akula et al., 2002), EBV
(Tugizov et al., 2003) and hantavirus (Gavrilovskaya et al.,
1999) bind to integrins through their RGD-containing glyco-
proteins. Human cytomegalovirus (HCMV) glycoproteins B
(gB) and H (gH) also bind to integrins, but the binding is
mediated by RGD-independent motifs (Feire et al., 2004; Wang
et al., 2005). Nonenveloped viruses, such as adenovirus
(Davison et al., 2001; Huang et al., 1996), rotavirus (Ciarlet
et al., 2002; Graham et al., 2003), foot-and-mouth disease virus
(Jackson et al., 1997), West Nile virus (Chu and Ng, 2004; Lee
et al., 2006), echovirus (Triantafilou and Triantafilou, 2001) and
coxsackie virus (Williams et al., 2004), have RGD-containing
capsid proteins that bind to various integrin heterodimers. The
interactions of viral proteins and integrins activate integrin
signaling pathways, which may lead to virus entry into hostcells (Krishnan et al., 2006; Medina-Kauwe, 2003; Meier and
Greber, 2004; Pietiainen et al., 2004; Sharma-Walia et al., 2004;
Wang et al., 2005).
In this study, we investigated BMRF-2 protein expression in
B lymphoblastoid cell lines, polarized oral epithelial cells and
HL epithelium. Our findings show that BMRF-2 is expressed
during EBV lytic infection in B cells and oral epithelial cells.
We show that BMRF-2 is glycosylated through O-linked
oligosaccharides and efficiently transported to the cell surface,
and that mature EBV virions are associated with oligomeric
forms of BMRF-2. The BMRF-2 RGD domain binds to β1, α5,
α3, and αv integrins, indicating that BMRF-2 is a ligand for
these integrins.
Results
Expression of the BMRF-2 protein in EBV-infected B
lymphocytes and polarized oral epithelial cells
To examine BMRF-2 expression in B lymphoblastoid cell
lines, EBV-infected B95-8 and P3HR-1 cells were treated with
30 ng/ml of PMA for 9 days. PMA-treated and untreated EBV-
negative BJAB cells were used as a negative control. At 1, 3, 5,
7 and 9 days post-treatment, cells were fixed and immuno-
stained for BMRF-2. To confirm induction of the EBV lytic
cycle, these cells were immunostained with EBV gp350/220.
Confocal immunofluoresecence analysis showed that BMRF-2
expression was detected in PMA-treated B95-8 and P3HR-1
cell lines, and protein localization was predominantly in the
cytoplasm (Fig. 1A). Co-immunostaining of BMRF-2 with
gp350/220 in these cells showed co-localization of these two
proteins (data not shown). Analysis of B95-8 and P3HR-1 cells
not treated with PMA showed that 0.8% and 0.3% of cells,
respectively, were weakly positive for BMRF-2 expression.
Quantitative analysis of BMRF-2-expressing cells showed that
BMRF-2 induction was detected in PMA-treated B95-8 and
P3HR-1 cell lines at 24 h post-treatment (Fig. 1B). At this time,
about 4.8% and 2.1% of B95-8 and P3HR-1 cells, respectively,
were positive for BMRF-2. There was a significant increase in
cells expressing BMRF-2 at 3 days post-treatment, reaching
8.5% and 3.4% in B95-8 and P3HR-1 cells, respectively.
Expression of gp350/220 in both cell lines was slightly greater
(2–3%) than that of BMRF-2 at 3 days post-treatment.
Expression of BMRF-2 and gp350/220 in these cells at 7 and
9 days post-treatment decreased by about 10–30% compared
with their expression at 3 days post-treatment.
Earlier we established the EBV-permissive polarized HSC-3sort
tongue and Detroitsort pharyngeal epithelial cell model (Tugizov
et al., 2003). These cells are highly positive for β1- and αv-family
integrins and the epithelial differentiation markers involucrin and
keratin-1 (manuscript in preparation). The efficiency of EBV
infection in these cells is dependent on epithelial cell differentia-
tion and polarization. To study BMRF-2 expression, polarized
HSC-3sort tongue and Detroitsort pharyngeal cells were infected
with the EBV B95-8 strain; at 1, 3, 5, 7, and 9 days post-infection,
cells were immunostained with rat anti-BMRF-2 antiserum.
Analysis showed that none of the proteins was detected at 24 h
Fig. 2. Expression of BMRF-2 in polarized HSC-3sort tongue cells. (A) Polarized
Detroitsort and HSC-3sort cells were infected with EBV from their basolateral
membranes for 1, 3, 5, 7 and 9 days and immunostained for BMRF-2 and
gp350/220 proteins. Cells expressing BMRF-2 and gp350/220 were counted
from triplicate samples and their average number was presented in %. Error bars
show SEM (n=3). (B) Polarized HSC-3sort cells were infected with EBV for
7 days and immunostained for BZLF-1, BMRF-2 and gp350/220 (green)
proteins. The cell nuclei were stained with propidium iodide (red).
Fig. 1. Expression of BMRF-2 in EBV-infected B lymphoblastoid cells. (A)
P3HR-1 and B95-8 cells were treated with 30 ng/ml PMA for 5 days and
immunostained with rat anti-BMRF-2 antiserum (green). EBV-negative BJAB
cells also were treated with PMA and were used as a negative control. Cell
nuclei were stained with propidium iodide (PI) (red). (B) Quantitative analysis
of P3HR-1 and B95-8 cells expressing BMRF-2 and gp350/220. P3HR-1 and
B95-8 cells were treated with 30 ng/ml PMA for 1, 3, 5, 7 and 9 days and then
immunostained for BMRF-2 and gp350/220. EBV-infected cells expressing
BMRF-2 and gp350/220 were counted. Error bars show SEM (n=3).
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number of cells (about 0.1–0.5%) showed a weak signal for both
proteins (data not shown). Significant expression of BMRF-2 in
both Detroitsort and HSC-3sort cell lines was detected at 3 days
post-infection (i.e., 5.3% and 2.5% cell were positive for
BMRFQ2, respectively) (Fig. 2A), at which time the expression
level of gp350/220 in Detroitsort and HSC-3sort cell lines was
slightly lower than that of BMRF-2. At 5 days post-infection,
however, the expression level of gp350/220 was about 2% higher
than that of BMRF-2 (Fig. 2A). At 5 days post-infection, BMRF-
2 expression was detected in 8.5% and 5.2% of Detroitsort and
HSC-3sort cells, respectively. The level of expression of BMRF-2
and gp350/220 in both polarized cells after 7 and 9 days post-
infection was stable. The stable expression of BMRF-2 and
gp350/220 in Detroitsort cells was observed for 3–4 weeks.
Expression of BMRF-2 and gp350/220 in HSC-3sort cells after
2 weeks of infection was significantly reduced, with approxi-mately 0.5% and 0.7% cells being positive for BMRF-2 and
gp350/220 proteins, respectively.
Dissociation of these EBV-infected polarized cells from the
filters and growing them under non-polarized conditions failed
to result in EBV-infected epithelial cell lines. The majority of
these cells (about 90%) in the flask were dead within 3–5 days
and only 5–10% of the surviving cells generated new cell
populations within the next 2–3 weeks. These cells were
negative for BMRF-2 and gp350/220 proteins, as well as for
EBV-latent proteins LMP1 and EBNA-1 (data not shown). PCR
and RT-PCR analysis also did not reveal EBV DNA or RNA
(data not shown). Localization of BMRF-2 protein in polarized
HSC-3sort (Fig. 2B) and Detroit sort cells (data not shown) was
predominantly in the cytoplasm, and a small amount of protein
was detected in the perinuclear area. The staining pattern of
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staining of BMRF-2 and gp350/220 showed co-localization of
these two proteins (data not shown). BZLF-1 was localized
exclusively in the nuclei (Fig. 2B).
BMRF-2 protein is transported to the cell surface
To determine whether BMRF-2 is expressed on the cell
surface in EBV-infected cells, we performed flow cytometry
analysis of EBV-infected B95-8 lymphoblastoid cells and EBV-
negative BJAB cells as a negative control, treated with 30 ng/ml
PMA and 4 mM butyric acid for 5 days. HSC-3sort cells were
infected with EBV from basolateral membranes and were
studied at 7 days post-infection for flow cytometry. To confirm
that the level of EBV infection was sufficient to evaluate
the surface transport of EBV glycoproteins, we also studied
gp350/220 in the plasma membranes of these cells. The results
showed that BMRF-2 protein was present on the surface of both
HSC-3sort and B95-8 cells (Fig. 3), indicating that BMRF-2 is
efficiently transported to the surface in EBV-infected cells.
Because the rat anti-BMRF-2 serum rose against the GST-
BMRF-2 RGD domain, these data indicated exposition of the
BMRF-2 RGD motif on the cell surface.
BMRF-2 is accumulated within the lateral membranes of the
HL epithelium and is transported to the basolateral
membranes of polarized oral epithelial cells
To examine BMRF-2 expression in HL lesions, cryosec-
tions from three HL biopsies were immunostained for
BMRF-2 protein. These data showed that BMRF-2 expres-
sion was detected within the stratum spinosum and stratum
granulosum layers of HL (Fig. 4A). In parallel experiments,
the sections from the same HL biopsies were immunostained
for BZLF-1 (Figs. 4B and C), which was detected in the
nuclei of spinosum and granulosum cells of the HLFig. 3. Transport of BMRF-2 to the cell surface. Polarized HSC-3sort cells were
infected with EBV from their basolateral membranes; at 7 days post-infection,
BMRF-2 expression was detected by flow cytometry analysis. Black shading
indicates uninfected cells, and the dotted line indicates infected cells. EBV-
infected B95-8 and EBV-negative BJAB cells were treated with PMA for 5 days
and analyzed by flow cytometry. Black shading indicates PMA-untreated cells
and the dotted line indicates PMA-treated cells. For flow cytometry assay, rat
anti-BMRF-2 antibodies were used.epithelium, where lytic EBV replication and viral dissemina-
tion occur. To determine the distribution of BMRF-2 in the
HL epithelium in more detail, the cryosections were
costained for BMRF-2 and BZLF-1, and images were
analyzed in an x–z vertical plane. These experiments showed
that BMRF-2 protein accumulated within the lateral mem-
branes of oral epithelial cells within the spinosum (Fig. 4D)
and granulosum (data not shown) layers.
Accumulation of BMRF-2 within the lateral borders of the
HL epithelium suggested that BMRF-2 might be delivered
specifically to the lateral membranes of oral epithelial cells. To
confirm this possibility, we examined its localization in EBV-
infected polarized Detroitsort cells. Because we found that β1
family integrins transport to the basolateral membranes of
polarized epithelial cells (De Luca et al., 1990; Muza-Moons
et al., 2003; Tugizov et al., 2003), we co-immunostained β1
integrin with BMRF-2 as a control marker. Non-permeabilized
polarized cells were immunostained from apical or basolateral
surfaces. Co-immunostaining of BMRF-2 and β1 integrin from
the apical membranes of polarized Detroitsort cells did not show
apical staining for both proteins (Fig. 5A, upper panel). In
contrast, basolateral staining of non-permeabilized Detroitsort
cells showed that both BMRF-2 and β1 integrin were present
and co-localized at the basolateral membranes (Fig. 5A, lower
panel). Analysis of these cells in x–z vertical plane also
confirmed basolateral transport and co-localization of BMRF-2
and β1 integrin (Fig. 5B).
BMRF-2 is associated with the envelope of mature virions
We and others have shown that BMRF-2 is associated with
mature EBV virions (Johannsen et al., 2004; Tugizov et al.,
2003); however, the presence and monomeric or oligomeric
status of BMRF-2 in the mature virion envelope were not
determined. To address these questions, we performed addi-
tional experiments using sucrose gradient-purified EBV virions
from B95-8 cells. To detect the BMRF-2 protein, the viral
proteins were separated on a 4–20% gradient Tris–glycine
SDS-PAGE gel and blotted with rat anti-BMRF-2 antiserum
(Fig. 6A). These data showed the presence of 55–60 kDa bands
and more diffuse bands with a higher molecular mass including
a solid band above 220 kDa (Fig. 6A). Normal rat serum did not
detect any protein bands in gradient-purified EBV (Fig. 6A),
confirming the specificity of the rat anti-BMRF-2 serum to EBV
BMRF-2. The electrophoretic mobility of the BMRF-2 protein
on a non-gradient 10% or 16% SDS-PAGE gel showed that it
migrated poorly in these gels with little entering the separation
gel (data not shown). Comparative analysis of BMRF-2 and
EBV viral capsid antigen (VCA) p160 in increasing concentra-
tion of total viral proteins in the same gel showed that BMRF-2
protein was detectable only when higher concentrations of EBV
proteins were loaded (i.e., 9–12 μg/lane) (Fig. 6B).
To examine the presence of BMRF-2 in the virion
envelope, the double-gradient purified virions from Nycodenz
gradient were extracted with Triton X-100 and 0.5% deoxy-
cholate, and tegument/capsid proteins were separated from
the envelope by high-speed centrifugation. Western blot
Fig. 4. BMRF-2 expression in oral hairy leukoplakia. (A) Cryosections of HL were immunostained with rat anti-BMRF-2 immune serum (green) and (B) mouse mAb
to BZLF-1. Magnifications: ×800. (C) HL section was immunostained for BZLF-1 using mouse mAb. Magnifications: ×200. (D) HL section was co-immunostained
for BMRF-2 (green) and BZLF-1 (red). Magnifications: ×1200. (A–C) Images were taken on an x–z horizontal plane and (D) images were taken in x–z vertical plane.
Cell nuclei in all panels were counterstained with TO-PRO-3 (blue).
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that BMRF-2 was present in the supernatant, which indicates
its association with the envelope (Fig. 6C). VCA p160 was
present in pellet fractions, as expected. These results indicate
that BMRF-2 is a component of mature EBV virions and that
it is associated with the virion envelope. To determine the
status of BMRF-2 in the virion envelope, EBV proteins were
separated on 7.5% native acrylamide gel. Total viral proteins
were extracted and separated under native, non-reduced, or
reduced conditions, and BMRF-2 protein was detected using
a Western blot assay. These results showed that the size of
the native (not treated with denaturing agents and heat)
BMRF-2 protein was approximately 220–240 kDa (Fig. 6D).
Under reduced condition, multiple bands of 55–58 kDa, 120–
140 kDa and 220–240 kDa were detected (Fig. 6D). Detec-
tion of 220–240 kDa BMRF-2 bands in native EBV virion
samples was consistent with the presence of oligomeric forms
of BMRF-2 in the virion envelope. The 55–58 kDa and
120–140 kDa bands under reducing and non-reducing condi-
tions represented monomer and dimer forms of BMRF-2,
respectively. It is possible that solid bands above 220 kDa
detected in denaturing gel (Figs. 6A and B) also may represent
an oligomeric form of BMRF-2, but because of the highly
hydrophobic nature of the protein, these oligomers may not
dissociate completely under denaturing conditions.Expression of the BMRF-2 protein in transiently transfected
cells
To study expression of BMRF-2 protein in absence of other
EBV proteins, we cloned the BMRF-2 ORF from the EBV B95-
8 strain. The DNA fragment containing BMRF-2 ORF and its
upstream 300 bp promoter region was cloned into the
expression vector plasmid LNCX downstream of the CMV
early promoter. The protein was tagged either with the GFP
protein or the HA peptide for convenient visualization and
detection. Transfection efficiency of HSC-3sort tongue and
Detroitsort pharyngeal cells was very low; therefore we used
293T human kidney epithelial cells for BMRF-2 expression.
Protein expression was examined by detection of GFP signals
and HA signals, and by indirect immunofluorescence assays
using mouse mAb to HA and rat polyclonal antisera against
BMRF-2. BMRF-2 expression of both constructs was detected
in about 80% of 293T cells. BMRF-2 GFP was detected in the
cytoplasm of 293T cells (Fig. 7A), a finding consistent with the
localization of BMRF-2 in the cytoplasm in EBV-infected
lymphoblastoid and epithelial cells. Anti-HA antibody recog-
nized BMRF-2 expression in BMRF-2-HA transfected 293T
cells (Fig. 7B). Co-immunofluorescence analysis of cells
transfected with BMRF-2-HA using anti-HA and anti-BMRF-
2 antibodies showed that both antibodies localized BMRF-2 to
Fig. 5. Basolateral transport of BMRF-2 in polarized Detroitsort epithelial cells.
(A) EBV-infected polarized Detroitsort cells were fixed with 3% paraformalde-
hyde at 7 days post-infection. Cells were reacted with anti-BMRF-2 and anti-β1
integrin antibodies from the apical surface (upper panel) or the basolateral
surface (lower panel). The images corresponding to the apical and basolateral
membranes were obtained in x–z horizontal plane. (B). Analysis of BMRF-2
and β1 integrin co-staining in the x–z vertical plane. (A and B) Cell nuclei were
stained in blue and are shown in the merged panel. Yellow in the merged panel
indicates co-localization of BMRF-2 (green) and β1 integrin (red) signals.
Magnification: ×1200.
Fig. 6. Detection of EBV BMRF-2 in gradient-purified EBV virions. (A)
Purified EBV viral proteins (10 μg/lane) were separated on a 4–20% SDS-
PAGE gradient gel and BMRF-2 was detected using rat anti-BMRF-2 antiserum.
Normal rat serum was used as a control. (B) Purified EBV viral proteins were
loaded at 1, 3, 6, 9 and 12 μg/lane and subjected to Western blot analysis using
mouse mAb to VCA p160 and rat anti-BMRF-2 immune serum. (C) Double-
purified virions from Nycodenz gradient were extracted with Triton X-100 and
0.5% deoxycholate and tegument/capsid proteins were separated from the
envelope by high-speed centrifugation. Proteins were separated in 4–20% SDS-
PAGE gradient gel, and BMRF-2 and VCA p160 proteins were detected using a
Western blot assay using rat antiserum and mouse monoclonal antibody. Sup,
supernatant. (D) Total EBV proteins from purified virions were treated for non-
reducing (SDS and boiling), native (not treated with SDS or beta-mercaptoetha-
nol and heat) and reducing (SDS, β-MER/beta-mercaptoethanol and boiling)
conditions, and were separated on a 7.5% native polyacrylamide gel. BMRF-2
was detected using rat antiserum.
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authentic BMRF-2 protein (Fig. 7B).
Western blot analysis of BMRF-2 protein in 293T cells using
denatured Tris–glycine SDS-PAGE showed that the majority of
the protein was detected only as high molecular-weight bands of
more than 220 kDa (data not shown). This was also noted in the
detection of BMRF-2 from purified virions, possibly due to the
highly hydrophobic nature of this protein. To improve detection
of BMRF-2, we purified the membrane fraction from BMRF-2
transfected cells and separated the membrane proteins on a 7 M
urea denaturing gel. Blotting of this gel showed that membrane-
associated BMRF-2 was detected as two bands of about 55 and
60 kDa (Fig. 7C). However, a large portion of BMRF-2 protein
also was detected above 220 kDa, i.e., did not enter into
separation gel (data not shown).
BMRF-2 C-terminus is localized in the cytoplasm
Because we tagged the BMRF-2 C-terminus with HA
epitope, it may be possible to determine its localization within
the cell membrane. To examine this possibility, 293T cells were
transfected with a DNA plasmid containing the BMRF-2 gene
tagged with HA at its C-terminus. Flow cytometry analysis of
BMRF-2-HA in 293T cells using EBV-specific human sera
confirmed surface transport of BMRF-2 in 293 cells (Fig. 7D).However, flow cytometry assay using anti-HA antibodies did
not detect BMRF-2 protein on the cell surface. We showed in
Fig. 7B that the same anti-HA antibody recognized BMRF-2
protein in 293T cells, which was fixed with methanol/acetone
(i.e., permeabilized), indicating that anti-HA antibodies recog-
nize intracellular BMRF-2. The absence of BMRF-2 on the cell
surface using the same antibody by flow cytometry of live cells
indicates that the BMRF-2 C-terminal HA epitope for anti-HA
antibody is not accessible on the plasma membranes. These data
suggest that the C-terminus of BMRF-2 could be in the
cytoplasm, or it could be embedded in the plasma membrane.
Since it is hydrophilic, the more likely localization is the
cytoplasm.
BMRF-2 protein is glycosylated by O-linked oligosaccharides
To study intracellular localization and glycosylation of
BMRF-2 protein, HSC-3sort oral epithelial cells were trans-
duced with a retrovirus vector expressing BMRF-2-GFP. Co-
immunofluorescence analysis of BMRF-2 with the ER marker
Fig. 8. Glycosylation of BMRF-2. (A) HSC3sort cells were transduced with a
retroviral vector expressing BMRF-2-GFP. After 48 h, cells were fixed and co-
immunostained for BMRF-2 with ER or Golgi markers. ER and Golgi were
detected with staining for GRP94 and Rhodamine-Lens Culinaris Agglutinin,
respectively. BMRF-2 is shown in green fluorescence as a GFP fusion protein
and the ER and Golgi markers are shown in red fluorescence. Yellow indicates
colocalization of BMRF-2 with ER or Golgi markers. (B) The 293T cells were
transfected with the BMRF-2 gene for 48 h and the membrane fractions of these
cells were isolated. In a parallel experiment, total proteins from purified EBV
virions were extracted. Transfected cells and virion samples were treated with a
combination of neuraminidase and O-glycosidase, and with O-glycosidase and
neuraminidase independently. Untreated samples served as a control. Treated
and untreated samples were subjected to Western blot analysis using rat anti-
BMRF-2 immune serum and proteins were separated in 7 M urea gels.
Neu, neuraminidase; OG, O-glycosydase. Cells, 293T cells transfected with
BMRFQ2. Virions, gradient-purified EBV virions.
Fig. 7. Analysis of BMRF-2 protein expression in 293T human embryonic
kidney cells transfected with BMRF-2 gene. (A) 293T cells were transfected
with BMRF-2-GFP construct and at 48 h later cells were analyzed by confocal
microscopy. Magnifications: ×200. (B) 293Tcells were transfected with BMRF-
2-HA DNA construct. At 48 h after transfection, cells were fixed with methanol/
acetone and co-immunostained with mAb to HA and rat polyclonal antibody to
BMRF-2. Green represents HA staining, red represents BMRF-2 staining, and
yellow indicates the merging of the two colors. Magnifications: ×1200. (C)
Western blot analysis of BMRF-2 in 293Tcells. 293Tcells were transfected with
BMRF-2-HA DNA construct, at 48 h post-transfection, membrane-enriched
cellular proteins were isolated and separated on a 7 M denaturing urea gel.
BMRF-2 protein was detected using rat anti-BMRF-2 antibody. Untransfected
293T cells served as a negative control. (D) Surface transport of BMRF-2 in
293T cells transfected with BMRF-2 gene. 293T cells were transfected with
BMRF-2-HA DNA construct, 48 h later, cells were analyzed by flow cytometry
using human anti-EBV sera and mAb to HA.
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Agglutinin showed that BMRF-2 co-localized with ER and
Golgi markers (Fig. 8A), indicating that BMRF-2 is present in
ER and Golgi compartments. Co-localization of BMRF-2 with
ER and Golgi markers was detected also in 293T cells
transfected with the BMRF-2 gene (data not shown). These
data show that the intracellular sorting and biosynthetic
pathways of BMRF-2 protein are typical for viral glycoproteins,
which may undergo post-translational modifications by oligo-
saccharides. Analysis of the amino acid sequence of BMRF-2,
however, showed that it does not have consensus Asn-X-Ser/
Thr (X, any amino acid except Pro) motif for potential N-
glycosylation. The glycoprotein could be post-translationally
modified by O-linked oligosaccharides; therefore, we examined
BMRF-2 glycosylation by O-linked oligosaccharides in gra-
dient-purified virions and in 293T cells transfected only with the
BMRF-2 encoding sequence. Proteins from purified EBV
virions and the membrane fractions of 293T cells expressing
BMRF-2-HA were treated with neuraminidase and O-glycosy-
dase independently or in combination. The protein was
separated on urea gel and detected using a Western blot assay.
As shown in Fig. 8B, neuraminidase treatment alone resulted in
a significant reduction of molecular mass, indicating a high
degree of peripheral sialylation of the protein. Treatment with
O-glycanase resulted in a significant reduction of the upper
band and increased the intensity and mobility shift of the lower
band, suggesting that the heavier isoform of the protein is highly
glycosylated through O-linked oligosaccharides. Treatment ofproteins with the combination of O-glycanase and neuramini-
dase further decreased the size of the protein, indicating full
deglycosylation. These data demonstrate that BMRF-2 protein
in transfected cells and in the virion envelope was extensively
glycosylated by O-linked oligosaccharides.
Purified EBV virions and BMRF-2 protein are associated with
integrins
We have previously shown that purified, biotinylated EBV
and the GST-BMRF-2 RGD fusion protein can bind β1 and α5
integrins in vitro (Tugizov et al., 2003). Here we show that the
BMRF-2 glycoprotein is associated with mature extracellular
virions and that its RGD motif is exposed on the surface of the
viral envelope, suggesting that progeny EBV virions during
their intracellular transport and/or release may bind to integrins.
To examine the association of integrins and released progeny
virions, we determined if integrins were present in gradient-
purified EBV from B95-8 cells using a Western blot assay.
Detection of VCAp160 served as a control in this experiment.
The results showed that β1 integrin was present in purified EBV
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viral proteins was loaded (i.e., 6 μg/lane and above) (Fig. 9A).
Analysis of purified EBV samples from two independent lots
showed that both purified virions contained β1 integrin (data
not shown), indicating that the EBV-β1 integrin association is
consistent. Western blotting of double gradient-purified EBV
B95-8 also revealed β1 integrin in virions (data not shown),
indicating that the EBV-integrin association is not due to
contamination with integrin.
It has been shown that EBV may activate expression of αv
integrin in B cells (Huang et al., 2000). To further study the
relation between EBV and integrins, we searched for αv, β1,
α3, and α5 integrins in purified EBV virions and B95-8 cells
with and without PMA treatment. Our data showed that purified
EBV virions and in B95-8 cells contain α3, α5 and β1 integrins,
indicating that the mature EBV virions acquired these integrins
from host cells (Fig. 9B). In contrast, αv integrins were detected
only in host cell samples and not in virions; thus, the EBV-
integrin association is not because of contamination of purified
virions with these integrins. PMA treatment of B95-8 cells
resulted in a decrease, not an increase, of integrin expression.
Western blot analysis showed that B95-8 cells express β1, α3
and α5 integrins in their fully processed mature form and under-
processed precursor form (Fig. 9B), but only the fully processed
forms were detected in the virions. The size of virion-associated
β1 integrin was 180 kDa, which was larger than that of B95-8
cells (160/125/116 kDa), indicating that highly processed
180 kDa integrin was not detectable in B95-8 cells by Western
blot assay, i.e., only very low level of this highly processed form
of β1 integrin is expressed in these cells. The presence of highly
processed integrins in EBV virions suggests that EBV
preferentially binds fully processed integrins. To determine
whether the virion binding with integrins is mediated by the
BMRF-2 RGD domain, we performed a GST-BMRF-2 RGD
pull-down assay in B95-8 cell extracts, which showed that the
BMRF-2 RGD domain binds to fully processed β1, α5, and
α3 and αv integrins (Fig. 9C).Fig. 9. Association of purified EBV virions and BMRF-2 protein with β1, α3 and α
9 μg/lane, separated on a 10% SDS-PAGE gradient gel and examined for β1 integrin
(10 μg/lane) and PMA-treated or -untreated B95-8 cells were analyzed for β1, α3 an
integrins with GST-BMRF-2 RGD fusion protein. Total cellular proteins from PMA-t
fusion protein and separated on a 10% SDS-PAGE gel. Pull-down with GST aloneDiscussion
Using antibodies to BMRF-2 and integrins, BMRF-2 RGD
peptides, soluble forms of integrins and integrin ligands, we have
shown that interaction between the EBV BMRF-2 glycoprotein
and β1 and/or α5β1 integrins plays a significant role in EBV
infection at the basolateral membrane of polarized oral epithelial
cells (Tugizov et al., 2003). We have observed that
α3β1, αvβ3, and αvβ5 integrins also are involved in the
infection with EBV of polarized oral epithelial cells, but to a
lesser extent than are β1 and/or α5β1 integrins. In the present
work, we characterize EBVBMRF-2 protein expression in EBV-
infected B lymphoblastoid and polarized oral epithelial cells and
in HL. Analysis of BMRF-2 in EBV-infected B lymphoblastoid
cells and polarized tongue and pharyngeal epithelial cells
showed that this protein is expressed in both B cells and
epithelial cells. In EBV-infected B cells, BMRF-2 expression
was dependent on PMA treatment, indicating that BMRF-2
expression occurs during the lytic cycle of EBV replication. The
highest level of BMRF-2 expression in B cells was at 5 days
post-induction, and it declined after 5 days of protein expression.
In contrast, BMRF-2 expression reached its highest level in
polarized epithelial cells at 5 days post-infection, but this level of
expression was stable for 9 days in HSC-3sort and 3–4 weeks in
Detroitsort cells. EBV-infected polarized cells that was disso-
ciated from the filter inserts failed to grow into established EBV-
infected epithelial cell lines, indicating that polarization of oral
epithelial cells may be critical for EBVreplication. Development
of epithelial cell polarity leads to acquisition of a cuboidal cell
shape, which occurs prior to formation of epithelial sheets and
terminal differentiation of epithelium (Fujita and Braga, 2005;
Pilot and Lecuit, 2005; Sourisseau et al., 2006). Since EBV
replication in HL is restricted to the terminally differentiated
stratum spinosum and granulosum layers (Niedobitek et al.,
1991; Sandvej et al., 1992; Young et al., 1991), in vitro
polarization and differentiation of tongue epithelial cells may
generate a favorable environment for EBV replication.5 integrins. (A) Purified EBV virions were extracted and loaded at 1, 3, 6 and
and VCAp160 using appropriate antibodies. (B) Gradient-purified EBV virions
d α5 integrins using a Western blot assay. (C) Association of β1, α3, α5 and αv
reated and-untreated B95-8 cells were pulled down with the GST-BMRF-2 RGD
was performed as a control.
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sion in HL sections showed that BMRF-2 protein was present
within the spinosum and granulosum layers, where high-level
EBV replication occurs. These data support our earlier finding
that abundant mRNA transcription of the BMRF-2 gene was
detected in the more differentiated stratum spinosum cell
layer of HL (Palefsky et al., 1997; Penaranda et al., 1997).
Accumulation of BMRF-2 protein within the lateral borders of
oral keratinocytes suggests that it may be transported to the
lateral surface of oral epithelial cells. Indeed, these data were
well supported by the basolateral transport of BMRF-1 in EBV-
infected polarized Detroitsort cells.
BMRF-2 has a di-leucine and tyrosine motif YLLVTFIKS at
the 349–357 amino acid position of its tail that may serve as a
potential basolateral sorting signal. The C-terminus of the
protein is oriented to the cytoplasm, since it is not detectable on
the cell surface. It has been well documented that such motifs at
the cytoplasmic tail of cellular and viral glycoproteins may
serve as basolateral sorting signals that mediate transport of
viral and cellular glycoproteins from the trans-Golgi-network
(TGN) to the basolateral membranes of epithelial cells
(Rodriguez-Boulan et al., 2005; Rodriguez-Boulan and
Musch, 2005). Accumulation of BMRF-2 at the lateral borders
of the HL epithelium and its transport to the basolateral
membranes of EBV-infected polarized Detroitsort cells may be
due to basolateral sorting of BMRF-2 that may, in turn, be
critical for the cell-to-cell spread of progeny virions. Co-
localization of BMRF-2 with β1 integrin at the basolateral
membranes of EBV-infected epithelial cells suggests that the
BMRF-2–integrin interaction may play an important role in the
lateral spread of virus within the oral mucosal epithelium.
We have shown previously and in this report that BMRF-2 is
detectable in gradient-purified EBV virions (Tugizov et al.,
2003). Johannsen et al. (2004) also revealed BMRF-2 in
gradient-purified EBV virions; however, it was at very low
level and was detected at between 225 and 350 kDa. Complete
separation of BMRF-2 was not possible on a SDS-PAGE gel and
in urea gel systems. EBV BMRF-2 is a highly hydrophobic
protein with multiple potential transmembrane domains; conse-
quently, its full separation may not be possible. The actual
amount of BMRF-2 protein in mature virions could be much
greater than that detected in our studies and those of others
(Johannsen et al., 2004). BMRF-2 was detected in Triton X-100
soluble fraction of purified virions, showing its association with
the virion envelope. BMRF-2 also was detected by immunoe-
lectron microscopy in the envelope of extracellular EBV in HL
tissue (manuscript in preparation). Analysis of BMRF-2 in
purified EBV virions under native, reducing and non-reducing
conditions showed that it might be present in monomeric,
dimeric and oligomeric forms in mature virions.
It has been shown that BMRF-2 is glycosylated by O-linked
oligosaccharides in EBV-infected lymphoblastoid cell lines
(Modrow et al., 1992). In this report, we also found that BMRFQ2
is glycosylated by O-linked oligosaccharides in transfected
cells as well as in purified EBV virions. The mobility shift after
treatment with O-glycosidase was much greater than previously
reported by Modrow et al. (1992). We also found substantialreductions in size after neuraminidase treatment alone and with
a combination of neuraminidase and O-glycosydase. Treatment
with neuraminidase alone resulted in a decrease in size of 5–
10 kDa in both isoforms of BMRF-2, suggesting that sialylation
contributes significantly to its post-translation processing and
molecular weight. It is unclear whether sialylation modulates
the functions of BMRF-2, as others have reported that it may or
may not affect protein function (Arao et al., 1997; Pirie-
Shepherd et al., 1995, 1997). Treatment with O-glycosydase
alone primarily reduced the molecular size of the upper protein
band, indicating that the heavier isoform is more glycosylated
than the smaller one or carries no sialic acid. Treatment with
both neuraminidase and O-glycosydase reduced the molecular
mass to about 45 kDa, which is close to its predicted monomer
size of 39 kDa. The reason for the differences between our
findings and those of Modrow et al. (1992) is probably due to
the different techniques used for sample preparation and protein
separation. Detection of the fully glycosylated form of BMRF-2
in purified EBV virions suggests that only the fully processed
form may be associated with the virion envelope.
BMRF-2 was efficiently transported to the cell surface of
EBV-infected epithelial cell lines and lymphoblastoid cell lines,
and its RGD motif was exposed on the surface of the plasma
membranes. Recognition of BMRF-2 on the cell surface by
EBV-specific human serum from nasopharyngeal cancer
patients indicates that BMRF-2 may be a highly immunogenic
target for the humoral immune response. Localization of the
RGD domain of BMRF-2 on the surface of the virus envelope
indicates its accessibility for interaction with the integrins of
target cells. Because BMRF-2 in the virion envelope may be
present as oligomers, their multiple RGD motifs may bind to
integrins, leading to a strong binding of virions to the cell
surface.
Previously we have shown that BMRF-2 RGD and purified
EBV virionsmay bind toα5 andβ1 integrins from polarized oral
epithelial cells (Tugizov et al., 2003). Immunoelectron micro-
scopy analysis of EBV virions in HL showed that the virion
envelope contains BMRF-2 and β1 integrin (manuscript in
preparation). Here, we have shown that purified EBV virions
released from B95-8 cells contain β1, α5 and α3 integrins of
host cells. Virions released from B95-8 cells were associated
exclusively with the fully processed β1, α3 and α5 integrins,
which are present only in the sorting compartments of the TGN
and on the cell surface (Akiyama and Yamada, 1987; Hotchin
and Watt, 1992; Kazui et al., 2000; Kim et al., 1992; Wang and
Howell, 2000). This suggests that EBV association with
integrins may occur within the TGN and/or at plasma
membranes of B95-8 cells. Binding of GST-BMRF-2 RGD
with β1, α3, α5, and αv integrins indicates that the virion
association with integrins may be mediated via the BMRF-2
RGD motif. However, we cannot exclude a possible interaction
of other EBV glycoproteins such as gB and gH with integrins. It
has been shown that HCMV gB and gH bind to α2β1, α6β1 and
αvβ3 integrins via non-RGD motifs (Feire et al., 2004; Wang et
al., 2005). We have shown previously that antibodies to β1 and
α5 integrins and soluble forms of α5β1 and α3β1 integrins
inhibit EBV infection of polarized oral epithelial cells (Tugizov
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integrins did not interfere virus binding to cell surface integrins.
The functional role of integrin when bound to EBV virions is
not understood. It has been shown that integrins may directly
interact with Fc receptors (FcR) (Kindzelskii et al., 2000;
Lecoanet-Henchoz et al., 1995; Ortiz-Stern and Rosales, 2005;
Petty et al., 2002; Van Spriel et al., 2002), and this interaction
may lead to modulation of the immune response, such as
lymphocyte proliferation, antibody and chemokine/cytokine
secretion, antigen presentation and phagocytosis (Ortiz-Stern
and Rosales, 2003). Thus, EBV-associated integrins may
interact with the FcR of immune cells and thereby play a role
in EBV pathogenesis in vivo.
In summary, our data show that EBV BMRF-2 is a virion-
associated, highly hydrophobic viral glycoprotein with multiple
potential functional properties and that BMRF-2 is the ligand
for β1, α5, α3, and αv integrins. BMRF-2 interaction with
these integrins may activate integrin and integrin-associated
signaling pathways that may lead to regulation of virus
attachment, entry and cell-to-cell spread.
Materials and methods
Cells and virus
EBV-permissive polarized human squamous tongue HSC-
3sort and pharyngeal Detroitsort epithelial cell lines were
established using a fluorescence-activated cell-sorting approach
with UV-inactivated EBV virions (Tugizov et al., 2003). Cells
were grown in Dulbecco's Modified Eagle's medium (DME)
containing 10% fetal bovine serum (FBS) (HyClone), 200 mM
L-glutamine, 0.1 mg/ml streptomycin and 100 μg/ml penicillin.
A human embryonic kidney cell line (293T) and a retroviral
packaging cell line (ProPak A.52) were purchased from
American Type Culture Collection (ATCC,Manassas, Virginia).
Cells were grown in DME containing 10% FBS (HyClone),
200 mM L-glutamine, 0.1 mg/ml streptomycin and 100 μg/ml
penicillin.
The B95-8 EBV-producing marmoset B-lymphoblastoid cell
line, the P3HR-1 human Burkitt's lymphoma cell line and the
human EBV-negative BJAB Burkitt's lymphoma cell line were
maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum and antibiotics. EBV replication was induced in
B95-8 cells by adding 30 ng/ml 12-O-tetradecanoyl phorbol-13
acetate (PMA) and 4 mM butyric acid (both from Sigma) to the
growth medium for 10 days. Virus-containing medium was
clarified of cell debris by centrifugation at 5000 g for 15 min
and supernatant filtered first through 0.8-μm pore-size and then
through 0.45-μm pore-size filters (Millipore). Virus was
concentrated by high-speed centrifugation at 16,000 round per
minute for 90 min. The viral titer was determined by
quantitative real-time PCR assay using EBV BZLF-1 gene-
specific primers (forward 5′-AAA TTT AAG AGA TCC TCG
TGT AA ACA TC-3′ reverse 5′-CGC CTC CTG TTG CCG
CAG AT-3′) and fluorigenic probe (5′(6FAM)-ATA ATG GAG
TCA ACATCC AGG CTT GGG C (TAMRA)-3′) (Ryan et al.,
2004). The beta-globin gene was used as a positive control(forward 5′-TGG CCA ATC TAC TCC CAGGA-3′, reverse 5′-
CAT GGT GTC TGT TTG AGG TTG C-3′; fluorigenic probe
5′(6FAM)-CAG GGC TGG GCA TAA AAG TCA GGG C-
(TAMRA)-3′). Q-PCR analysis was performed on an AB Prism
7900 detection system (Applied Biosystems). Thermocycling
conditions were: 50 °C for 2 min, 95 °C for 10 min; 95 °C for
15 s and 60 °C for 1 min for 40 cycles. Each reaction contained
1× TaqMan® Universal Master Mix and with final concentra-
tions of 5.5 mM MgCl2, 200 μM dNTPs, forward and reverse
primer (20 pmol each), TaqMan® probe (10 pmol) and 0.5 units
Hotstart AmpliTaq® Gold (Applied Biosystems) in a 20-μl
volume in a 384-well plate. Experimental samples were run in
triplicate and the mean viral load was calculated. Every run had
at least two “no template” controls to check for amplicon
contamination. DNA from the Namalwa cell line (American
Type Culture Collection) containing two copies of EBV per cell
(Ryan et al., 2004) was used to generate standard curves.
Sucrose gradient-purified EBV virions (lot numbers: 106-
099, 13B-0008) were purchased from ABI Biotechnologies
(Columbia, Maryland). Released virus from B95-8 cells treated
with 30 ng/ml PMA and 4 mM butyric acid was purified on a
3%–60% sucrose gradient. Virions were collected between 41%
and 48% of the gradient and the purity of the virions was
examined by electron microscopy.
EBV infection of polarized cells on permeable filter supports
To establish a polarized monolayer, the cells were cultured
on 12-mm-diameter, 0.45-μm pore size, polycarbonate mem-
brane Transwell filters (Costar Corp., Cambridge, Massachu-
setts), which were coated with mouse laminin (10 μg/cm2)
(Sigma) (Tugizov et al., 2003). Polarized HSC-3sort tongue
(between passages 15–20) and Detroitsort pharyngeal (between
passages 12–18) cells were infected with cell-free EBVat 1000
multiplicity of infection (MOI)/cell through their basolateral
membranes. As only10% of virions may traverse filter pores
(Tugizov et al., 2003), the real MOI will be about 100 virions/
cell. The volume of virus inoculum was 250 μl. To allow virions
to traverse the filter pores, cells were incubated at 37 °C for 1 h
on a shaker, then washed with medium and maintained in DME
containing 10% FBS.
HL tissue biopsies
Biopsies of HL tongue tissue containing epithelium and
connective tissue were obtained using 4-mm-diameter biopsy
punches from 3 HIV-positive individuals. Biopsies were done
before highly active anti-retroviral therapy (HAART) was
available, and the tissues were frozen and stored in the tissue
bank of the Oral AIDS Center Clinic of the Department of
Orofacial Sciences, University of California, San Francisco.
The biopsy tissues were sectioned in slices 7 μm thick.
Antibodies
Polyclonal rat anti-BMRF-2 antibody designated as C2 was
previously generated in our laboratory by immunizing rats with
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domain of the BMRF-2 protein (aa 171–218) (Tugizov et al.,
2003). Monoclonal antibodies (mAbs) to EBV gp350/220 and
VCA p160 were purchased from ABI. mAb to EBV BZLF-1
was obtained from Dako (Carpinteria, California). mAb HA.11
against influenza hemmaggutinin (HA) was purchased from
Covance Research Products (Berkeley, California). EBV-
specific human serum was a gift from Dr. Evelyn Lenett
(Virolab Inc., Berkeley, California). Use of human sera was
approved by the Committee on Human Research Review Board
of the University of California, San Francisco (UCSF) (CHR
approval #RS00908). GRP94, a rat mAb for staining the
endoplasmic reticulum was purchased from NeoMarkers
(Fremont, California). Rhodamine-Lens Culinaris Agglutinin
for Golgi staining was purchased from Vector Laboratories Inc
(Burlingame, California). Antibodies to β1 (MAB2000), α5
(AB1949), α3 (AB1920) and αv (AB1930) integrins were
purchased from Chemicon (Temecula, California). All second-
ary antibodies were from Jackson ImmunoResearch Labora-
tories, Inc (West Grove, Pennsylvania).
PCR cloning
The expression vector plasmid, LNCX, is a retroviral vector
kindly provided by Dr. Michael Bishop at UCSF (Haddad
and Hutt-Fletcher, 1989). The BMRF-2 gene of EBV was
PCR-cloned from EBV genomic DNA of the B95-8 strain,
either tagged with the influenza hemagglutin (HA) epitope
(YPYDVPDYA) or with the enhanced green fluorescence
protein (GFP). The following primers were synthesized by
Qiagen/Operon Inc. (Valencia, California): BMRF-2–5′: ATG-
GAATTCTTTAACCACGCCTCCGAAGAG; BMRF-2–3′ha:
AAGGGAGGCATAATCCGGCACATCATAAGGGTAA-
CAGGATTTAATGAATGTTCACCAAC; BMRF-2–3′Bam:
ATGGGATCCGGATTTAATGAATGTTCACCAAC; Gfp5′
bam: ATGGGATCCGGTGGAGGTATGGTGAGCAAG-
GGCGAGGAG); Gfp3′: ATGGAATTCTTACTTGTACAG-
CTCGTCCATG). To clone the HA-tagged BMRF-2, primers
BMRF-2–5′ and BMRF-2–3′ha were used to amplify a product
corresponding to nucleotides 80701–82188 of the EBV
genome, which includes the coding sequence of BMRF-2 and
its upstream promoter region. To clone BMRF-2 tagged with
GFP, primers BMRF-2–5′ and BMRF-2–3′Bam were used to
amplify the BMRF-2 gene from EBV and primers Gfp5′bam
and Gfp3′ were used to amplify the GFP gene from plasmid
pIRES2EGFP (Clonetech, Palo Alto, California). The orienta-
tion of insertions in these two constructs was determined by
restriction digestion; two of each with the correct orientation
were sequenced by MClab (South San Francisco, California)
and the sequences were found to be identical to the published
sequence. Expression of the BMRF-2 protein was confirmed by
transient transfection followed by direct fluorescence micro-
scopy for the BMRF-2 GFP fusion protein or by immuno-
fluorescence staining using HA.11 (Convance) for the HA-
tagged protein. To express the RGD domain of BMRF-2 (aa
172–218) as a GST-fusion protein, the RGD fragment was
amplified by PCR using the following primers: BMRF-2RGD5′, ATGGGATCCTCTGGAAGCCTGGCCGGTGC;
BMRF-2RGD3′, GTCTTCCCACGGGCATTTATG. The PCR
products were cloned into pCR2.1 vector by Topo-cloning
(Invitrogen) to give pCR2.1/BMRF-2 RGD. The cloned
fragment was cleaved from pCR2.1/BMRF-2 RGD by restric-
tion digestion with BamHI and EcoRI and was gel-purified.
The DNA fragment was ligated with pGEX2-T (Amersham) cut
with the same restriction enzymes to create the GST-BMRF-2
RGD fusion plasmid.
DNA transfection and retroviral transduction
For transient expression of the BMRF-2 protein, plasmid
DNA carrying the BMRF-2 gene was transfected into 293T
human embryonic kidney cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer's protocols. Twelve
to 16 h before transfection, cells were seeded in 6-well plates or
10-cm Petri dishes to reach 80–90% confluence at the time of
transfection. Twenty-four to 36 h post-transfection, cells were
harvested for protein extraction or used for immunofluores-
cence staining or flow cytometry analysis. For stable expression
of the BMRF-2 protein, the BMRF-2 gene was transfected into
the retroviral packaging cell line ProPak A.52 as above for 48 h.
Supernatant was collected, clarified by centrifugation and
filtered with a 0.8-μM filter. The supernatant then was added
to the cell monolayer (5 ml/T-25 flask) and the cells were
incubated at 30 °C for 16–20 h. Cells were grown in normal
growth medium for another 24 h before G418 selection
(500 μg/ml) for 2–3 weeks. Neo-resistant colonies were then
screened for BMRF-2 expression either by GFP expression
(for the BMRF-2 fusion protein) or by immunostaining (for
BMRF-2-HA tagged protein).
Confocal immunofluorescence and flow cytometry assays
For immunofluorescence assays, EBV-infected polarized
HSC-3sort, Detroitsort cells, EBV-positive lymphoblastoid cells
P3HR-1 and B95-8, and EBV-negative BJAB cells were
washed with phosphate-buffered saline (PBS, pH 7.2), fixed
in freshly prepared 4% paraformaldehyde and 2% sucrose for
5 min, and permeabilized with 0.01% Triton X-100 in 4%
paraformaldehyde for 5 min. HL sections also were fixed as
described above. To reduce background signals, they were
incubated overnight with blocking buffer (3% bovine serum
albumin (BSA) in PBS. Before incubation with primary
antibodies, tissue sections were incubated with normal rat and
mouse sera (Jackson Immunochemicals) for 1 h. The 293T cells
transfected with BMRF-2 encoding sequence were fixed with
methonal/acetone (50:50) for 30 min at −20 °C.
EBV-infected B lymphoblastoid cells and oral epithelial cells
were immunostained with mAb to EBVBZLF-1, gp350/220 and
rat antiserum (C2) to EBV BMRF-2. To examine BMRF-2 and
BZLF-1 expression in HL tissue, sections were immunostained
with rat anti-BMRF-2 and mouse mAb to BZLF-1. To detect
HA-tagged BMRF-2 in 293T cells transfected with the BMRF-2
ORF, cells were immunostained with mAb HA.11. Cells were
washed twice with PBS and incubated with FITC-labeled
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esearch) at 37 °C for 30 min. Cells were analyzed using a
krypton–argon laser coupled with a Bio-Rad MRC2400
confocal head. The data were analyzed using Laser Sharp
software.
For surface immunofluorescence assays, Detroitsort cells
infected with EBVon permeable filters were washed with cold
PBS (pH 7.2), and fixed with fresh 3% paraformaldehyde on ice
for 5 min (Tugizov et al., 1998). Fixed cells were incubated on
ice with rat anti-BMRF-2 and mouse anti-β1 integrin antibodies
applied from the apical or basolateral surface for 30 min. Cells
were washed with cold PBS and permeabilized with 0.5%
Triton X-100 (5 min), and incubated with secondary anti-rat and
anti-mouse antibodies conjugated to FITC and Texas Red,
respectively applied to both surfaces. To examine apical and
basolateral staining, the polarized cells were scanned by con-
focal microscopy by obtaining z-sections in an x–z horizontal
plane or in an x–z vertical plane.
For flow cytometry assays, EBV-infected or BMRF-2
transfected cells were dissociated with enzyme-free cell
dissociation buffer (Difco), and incubated with primary
antibodies in PBS (pH 7.4) containing 1% BSA for 1 h on
ice. Cells were washed three times in PBS by centrifugation at
500×g for 3 min each and reacted with appropriate FITC-
labeled secondary antibodies for 30 min. Cells were analyzed in
a FACSCAN (Decton-Dickinson, San Jose, California).
Membrane protein extraction of BMRF-2-transfected 293T
cells
The method used to extract membrane-enriched proteins was
modified from Obermann et al. (2003). Confluent monolayers
of BMRF-2 transfected or mock-transfected 293T cells in
10-cm dishes were washed once with PBS and harvested in PBS
(1 ml/dish) by pipetting up and down several times. One-
twentieth volume of a cocktail of protease inhibitors (Sigma-
Aldrich, St. Louis, Missouri) was added to the cell suspension.
Cells were homogenized 3 times for 30 s at 28,000 rpm using a
Brinkmann Polytron PT3000 homogenizer (Brinkmann Instru-
ments, Westbury, New York). The homogenates were centri-
fuged at 1000×g (IEC Centra GP8R centrifuge, International
Equipment Company, Needham Heights, Massachusetts) for
10 min at 20 °C to remove nuclei and debris. Supernatants were
centrifuged at 16,000×g in an Eppendorf centrifuge at 4 °C for
60 min and the supernatants were discarded. The membrane-
enriched pellets were resuspended in buffer (50 μl/107 cells)
containing 50 mM Tris–HCl, 0.15 M NaCl, 2 mM CaCl2, 5 mM
KCl, 5 mM MgCl2, 4 mM EDTA, pH 7.5, with the same
protease inhibitors and stored at −80 °C in 50-μl aliquots.
Western blot assays
For detection of BMRF-2, sucrose gradient-purified EBV
virions (ABI Biotechnologies, Columbia, Maryland) were
extracted with radioimmunoprecipitation assay (RIPA) lysis
buffer containing nonionic detergents 1% NP-40, 1% NaDOC
(sodium deoxycholate), 0.1% sodium dodecyl sulfate (SDS),Tris, pH 8.0, and a cocktail of protease inhibitors: phenyl-
methylsulfonylfluoride (PMSF) (1 mM), aprotinin (10 μg/ml),
leupeptin (10 μg/ml) and pepstatin A (10 μg/ml). Viral proteins
were separated on a 4–20% gradient Tris–glycine gel (Invitro-
gen) and transferred to polyvinyliden-difluoride (PVDF)
membranes (Millipore, Eschborn, Germany). BMRF-2 and
VCA p160 in virions were detected using rat antiserum to
BMRF-2 and mouse mAb to p160, respectively. Protein bands
were visualized using the SuperSignal West Pico Chemilumi-
nescent Substrate Kit (Pierce, Rockford, Illinois) according to
the protocols provided by the manufacturer. To detect EBV
virion-associated integrins, viral protein from gradient-purified
virions was extracted using RIPA buffer and separated by 10%
Tris–glycine gels (Invitrogen), and integrins were detected using
appropriate anti-integrin antibodies.
For native gel electrophoresis, EBV proteins from gradient
purified virus (ABI) were extracted with RIPA lysis buffer. Viral
proteins then were divided into three tubes and treated as
follows: with sample buffer without SDS, beta-mercaptoethanol
and boiling (native); with sample buffer containing 2% SDS
without beta-mercaptoethanol (non-reduced); and with sample
buffer containing 2% SDS and 0.5% beta-mercaptoethanol
(reduced). Each sample was loaded at 10 μg/lane onto a 7.5%
native Tris–glycine gel. Running buffer consisted of 40 mM
boric acid, pH-adjusted to 8.65 by adding solid Tris base;
stacking gel containing 5% acrylamide/bis-acrylamide (16/1),
0.1% SDS and 50 mM Tris–HCl, pH 6.1; and resolving gel
containing 7.5% acrylamide/bis-acrylamide (10/1), 0.1% SDS
and 50 mM Tris–HCl, pH 9.18. Proteins were transferred to
PVDF and BMRF-2 was detected with rat anti-BMRF-2 serum.
For urea gel electrophoresis, the membrane fraction of 293T
cells transfected with the BMRF-2 gene was solubilized in urea
sample buffer (7 M urea, 2 M thiourea, 1% TX100, 1% DTT,
4% chaps and 10 mM Tris, pH 9.5) at room temperature for 1 h.
Samples were mixed with one-tenth volume of 1 M DTT and
denatured at 70 °C for 10 min. Proteins were separated with 7 M
of urea-SDS PAGE (Resolving gel: 10% polyacrylamide, 7 M
urea, 0.2% SDS, 250 mM Tris, pH 9.0. Stacking gel: 4%
polyacrylamide, 7 M urea, 0.2% SDS, 250 mM Tris, pH 6.8).
Proteins were transferred to the PVDFmembranes and BMRF-2
was detected with rat anti-BMRF-2 antibody.
Detection of BMRF-2 in the virion envelope
To separate EBV-envelope proteins from tegument/capsid
proteins, extracellular virions released from B95-8 cells were
double purified in Nycodenz (Sigma) gradient. B95-8 cells were
treated with 30 ng/ml PMA and 4 mM butyric acid for 10 days,
and media were collected and cleared from cell debris by
centrifugation three times at 8000×g for 15 min. Supernatant
was filtered through 0.45-μm pore-size filters. Virions were
pelleted at 16,000 rpm for 1 h and resuspended in 1× TNB
buffer (0.01 M Tris–HCl, pH 7.2, 0.15 M NaCl) with 100 μg/ml
bacitracin (Sigma) in 1/100 of the original volume. The
concentrated virus particles were centrifuged through a 24–
42% Nycodenz (Sigma) step gradient at 21,000 rpm (70,000×g)
for 1 h using a Sorvall TH641 rotor (Lake and Hutt-Fletcher,
394 J. Xiao et al. / Virology 359 (2007) 382–3962000). The virus band at the 24–26% interface was collected.
The virions were then diluted with 1× PBS and pelleted at
19,000 rpm (60,000×g) for 2 h. The pellet was resuspended in
1× PBS and further purified through a 24–42% continuous
Nycodenz gradient. After the second purification, virions were
pelleted and extracted with RIPA buffer containing 1% Triton
X-100, 0.5% deoxycholate (DOC) and a cocktail of protease
inhibitors for 30 min at 37 °C. The viral extract was separated
into supernatant containing envelope proteins and pellet
containing tegument/capsid proteins by centrifugation at
100,000×g for 1 h (Zhu et al., 2005). Equal amounts of protein
from the supernatant and pellet were separated in 4–20% Tris–
glycine gel, and BMRF-2 and VCA p160 were detected using
rat antiserum and mouse monoclonal antibody, respectively.
EBV BMRF-2 endoglycosidase treatment assay
Membrane proteins or gradient-purified EBV virions were
treated with glycosidases as described by Tarentino et al.
(Tarentino and Plummer, 1994). Briefly, 40–50 μg of proteins
was denatured at 95 °C for 5 min in 0.5% SDS, 0.5% β-
mercaptoethanol in 25 μl volume with 2.5 μl of protease
inhibitor cocktail (Sigma-Aldrich). Samples were digested
overnight in a 50-μl reaction with 3.3% (v/v) nonidet P-40, 2
mU (5 μl) of O-glycosidase or neuraminidase, or both, in
50 mM sodium phosphate, pH 5.0. Enzymes were inactivated
before loading onto SDS-PAGE by mixing with equal volumes
of 2× urea sample buffer (12 M urea, 4 M thiourea, 8% Chaps,
2% Triton X-100, 2% DTT, 40 mM Tris, pH9.5) and heating at
70 °C for 10 min.
GST pull-down assays
GST fusion proteins were purified using glutathione
Sepharose 4B columns according to the protocol provided
by the manufacturer (Amersham). Total cellular proteins were
extracted with RIPA buffer and centrifuged at 14,000×g
for 30 min at 4 °C. The supernatant was incubated with
20 μg/ml of GST-BMRF-2 RGD (amino acid 171–218) pre-
bound to glutathione-sepharose beads at 4 °C and gently
rocked for 1 h. The beads were washed three times with RIPA
buffer, treated at 95 °C for 5 min with SDS sample buffer
containing 5% β-mercaptoethanol and used for Western blot
analysis.
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